Patrick Neven, Sileny N. Han. "PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER+HER2− breast cancer harbouring acquired ESR1 mutations." Nature Reviews Clinical Oncology, 2025. doi:10.1038/s41571-025-01062-6